Mergers and acquisitions: buying a company

A bigger, richer company spots a smaller rival with a clever product. It announces a deal: it will buy the smaller firm for half a billion pounds. The press calls it bold. The chief executive calls it the future. The two share prices move that morning — and here is the strange part. The bought company’s shares jump. The buyer’s shares fall. The market has just looked at a triumphant deal and decided the winner is the one being sold. To understand why, you have to understand the single most reliable trap in corporate finance: most acquisitions destroy value for the company doing the buying.

What an acquisition is, and why anyone bothers

An acquisition is one company buying another. Sometimes it’s friendly, sometimes a fight, but the shape is the same: the buyer pays, and owns the target afterwards.

The reasons sound good in a boardroom. Grow faster than you could on your own. Get something you can’t easily build — a product, a customer list, a brand, a patent. Take a rival off the board. And the word that sells almost every deal ever done: synergies — the idea that the two companies are worth more joined than apart. Shared costs (one finance team instead of two), cross-selling (sell the buyer’s product to the target’s customers), more bargaining power. Synergy is the promise that two and two will make five.

The buyer can pay in cash, in its own shares, or a mix. Either way, real value leaves the buyer’s hands. The whole question is whether more value comes back.

The premium: why you always pay too much

Here is the catch that does the damage. To buy a company, you have to pay more than it is worth on its own.

That sounds backwards. It isn’t. The target’s owners already hold something worth its standalone value. They will not hand it over for exactly that — they’d gain nothing. To get them to sell, you offer extra. That extra is the premium: the amount you pay above the target’s value as it stands alone.

So the deal only pays off if one thing is true: the synergies you create are bigger than the premium you paid. The premium is real money, gone the day the deal closes. The synergies are a forecast — a hopeful number, made by the people who want the deal to happen. Guess which one tends to be wrong.

A worked example: A buys B

Walk it slowly, with numbers.

Company A is worth £1 billion. It wants to buy Company B, which is worth £400 million on its own. To win B’s owners over, A offers £500 million — that’s £100 million over B’s standalone value. The £100 million is the premium.

Now the only question that matters: what is B actually worth to A once they’re joined? That’s B’s £400 million plus whatever synergies A can squeeze out.

The good case. Say A genuinely creates £150 million of synergies — shared costs, real cross-selling. Then B is now worth £400m + £150m = £550 million to A. A paid £500 million for something worth £550 million. Value created: +£50 million. A good deal — the synergies (£150m) beat the premium (£100m).

The usual case. Now say the synergies come in at only £40 million — the cost savings were harder than the slides claimed, the cross-selling never materialised. B is worth £400m + £40m = £440 million to A. But A paid £500 million. Value destroyed: −£60 million. The company got bigger. It got worse. A’s owners are £60 million poorer, even as the headline celebrates the deal.

The line between the two cases is exact: the deal breaks even when synergies equal the premium — here, £100 million. Below that line, you have paid for a company and quietly handed money to its former owners.

The winner’s curse

Now add the thing that makes it worse: a bidding war.

Suppose several companies want B. Each makes its own private guess at how much B is worth to them — and those guesses are scattered, some too low, some too high. Who wins the auction? Not the one with the best plan. The one who guessed highest — which usually means the one who most overestimated B’s value. Winning the bid often means you were the most wrong in the room.

This is the winner’s curse: in a competitive sale, the winner is frequently the one who overpaid. Each bidder, trying to beat the others, pushes their offer up — past a sensible price, past the break-even, into the zone where even decent synergies can’t cover the premium. The auction rewards optimism, and optimism is exactly what you don’t want pricing a deal.

So the buyer carries all the risk. The synergies are theirs to deliver, the premium is theirs to pay. The target’s shareholders? They pocket the premium and walk away the moment the deal closes. Their job is done. They sold high.

Reading the deal

When a deal is announced as “A buys B for £500 million,” the story is told as the buyer’s victory. The buyer is doing the acting; the buyer’s name is on the headline. But look again at who actually wins. B’s shareholders got £500 million for a £400 million company — a clean £100 million gift. A’s shareholders got a company they have to make work, at a price that only pays off if a forecast made by deal-hungry executives turns out to be right.

If you hold a broad fund, you own pieces of the buyers and the sellers. On the buying side, your money is the premium being paid out and the synergies being hoped for. The graveyard of corporate strategy is full of triumphant mergers that quietly cost the buyer’s owners a fortune — not because growth is bad, but because growth bought at a premium isn’t growth at all until the synergies show up, and they so often don’t. Bigger and better are not the same thing, and the gap between them is exactly the number nobody puts in the press release.